• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day

    11/14/24 6:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • Dexcom unveils new global data1 which reveals nearly 70% of people with diabetes say they didn't know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest
    • Alongside Dexcom Warriors and Stelo Ambassadors, Dexcom invites people with diabetes to share their aspirations – whether small or large – helping them take the first step in their health journey to discover what they're made of
    • In the U.S., Dexcom is hosting a giveaway for Dexcom G7 and Stelo users to increase community engagement and awareness of the incredible things people with diabetes can achieve

    This World Diabetes Day, DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they're made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn't know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114889138/en/

    Dexcom is teaming up with its thousands of global brand advocates – Dexcom Warriors and Stelo Ambassadors, including Nick Jonas, Lance Bass, Retta, Ed Gamble, Molly Sandén and more – to inspire and motivate people with all types of diabetes to take the first step toward discovering what they're made of. (Photo: Business Wire)

    Dexcom is teaming up with its thousands of global brand advocates – Dexcom Warriors and Stelo Ambassadors, including Nick Jonas, Lance Bass, Retta, Ed Gamble, Molly Sandén and more – to inspire and motivate people with all types of diabetes to take the first step toward discovering what they're made of. (Photo: Business Wire)

    For National Diabetes Awareness Month in the U.S. and Canada (November) and on World Diabetes Day (Nov. 14), Dexcom is teaming up with its thousands of global brand advocates – Dexcom Warriors and Stelo Ambassadors, including Nick Jonas, Lance Bass, Retta, Ed Gamble, Molly Sandén and more – to invite people with diabetes to share something they're striving toward on social media – whether it be a new goal, new habit, new beginning or new adventure. By bringing this community together, Dexcom aims to inspire and motivate people with all types of diabetes to take the first step toward discovering what they're made of.

    As part of the campaign, Dexcom surveyed people with diabetes around the world (U.S., U.K., Germany, Poland, Canada, Japan, Netherlands, Australia and New Zealand) and found that 85% of respondents believe that taking small steps to managing diabetes can lead to significant improvements in overall wellbeing. In addition, 84% of current tech users say that technology, such as a CGM or a glucose biosensor, can help those managing diabetes achieve their dreams.

    This new data further emphasizes the importance of technology in helping people better manage their diabetes and demonstrates the significance of Dexcom's relentless commitment to innovation. The company recently added to its portfolio of products with the launch of award-winning2 Stelo, the first over-the-counter glucose biosensor in the U.S., and Dexcom ONE+, the latest CGM system in Europe using Dexcom's best-in-class sensor platform. Both of these product launches help improve access to life-changing CGM and glucose biosensing, giving even more people with diabetes the peace of mind they need to achieve their dreams.

    "At Dexcom, we know better health empowers us all, and I believe World Diabetes Day is the perfect time to change the perception of what's possible," said Kevin Sayer, president and chief executive officer at Dexcom. "Our community of users, caregivers, and physicians have inspired us—and we hope that by delivering critical health information across our portfolio of leading glucose biosensors we're able to do the same. As we build on our legacy of pioneering this industry, we're committed to helping people at any age and any stage of diabetes receive the information and tools they need to discover what they're made of."

    "A diabetes diagnosis can feel isolating. With the right support and tools, like Dexcom biosensing technology, it doesn't have to be," said Nick Jonas, multi-platinum recording artist, songwriter, actor and philanthropist. "I'm part of a community that's living proof of what people with all types of diabetes can achieve, and this World Diabetes Day, we hope to inspire others around the world to truly discover what they're made of—and embrace their full potential to live beyond their diagnoses."

    In the U.S., Dexcom is hosting a giveaway to inspire people with diabetes to take their first step towards a goal, habit or journey to change their perception of what's possible. During the month of November, people with diabetes are invited to share their aspirations, small or large. Whether it's logging the first mile for a 5K run, committing to learn a new language or signing up for a cooking class, every journey starts with taking the first step to discover what you're made of. Dexcom will help empower that first step by randomly selecting participants to win a $500 prize to jumpstart their journey.

    To join the conversation this National Diabetes Awareness Month and World Diabetes Day, share #DiscoverWithDexcom on Instagram and TikTok. Dexcom and Stelo users can enter the U.S. giveaway by visiting Dexcom.com/G7Giveaway or Dexcom.com/SteloGiveaway.

    About Dexcom

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    Survey Methodology

    Dexcom surveyed 2,250 individuals over the age of 18 living with Type 1 or Type 2 diabetes. 250 individuals were sourced from each of the following markets: Australia, Canada, Germany, Japan, the Netherlands, New Zealand, Poland, the UK and the US. The survey was fielded in October 2024 using Forsta, and panel was sourced from ResearchDesk by RepData.

    1 Dexcom, data on file, 2024.

    2 (2024). Best Inventions of 2024, TIME.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241114889138/en/

    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    10/21/2025$85.00Buy
    Stifel
    9/8/2025Outperform → Perform
    Oppenheimer
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Dexcom with a new price target

    Stifel resumed coverage of Dexcom with a rating of Buy and set a new price target of $85.00

    10/21/25 7:19:41 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom downgraded by Oppenheimer

    Oppenheimer downgraded Dexcom from Outperform to Perform

    9/8/25 8:40:02 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Argus initiated coverage on Dexcom with a new price target

    Argus initiated coverage of Dexcom with a rating of Buy and set a new price target of $100.00

    8/21/25 8:05:28 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    11/10/25 9:52:13 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by DexCom Inc.

    10-Q - DEXCOM INC (0001093557) (Filer)

    10/30/25 5:19:54 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    10/30/25 4:02:39 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Collins Richard Alexander sold $217,811 worth of shares (3,948 units at $55.17) (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:12:40 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Ashley Euan A. was granted 7,166 shares (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    10/28/25 4:49:22 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Leach Jacob Steven bought $1,001,702 worth of shares (18,200 units at $55.04), increasing direct ownership by 6% to 331,697 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    11/10/25 7:13:08 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will hold a conference call to review the company's third quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

    10/2/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

    7/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Québec Expands Access to Dexcom CGM under the Régie de l'assurance maladie du Québec (RAMQ)

    New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, Inc. (NASDAQ:DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l'assurance maladie du Québec (RAMQ) for eligible Québecers aged 18 and older living with type 2 diabetes who are treated with intensive insulin therapy (IIT)*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106123887/en/Quebec

    11/6/25 8:34:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $242.5 million or 20.1% of revenue, an increase of 480 basis points compared to the third quarter of 2024. Non-GAAP operating income* of $272.9 million or 22.6% of reported revenue, an increase of 130 basis points compared to the third quarter of 2024.

    10/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Appoints Euan Ashley to Board of Directors

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at Stanford University, overseeing Stanford's largest department with 15 divisions and over 800 faculty. Dr. Ashley's research extends across precision medicine, data science, artificial intelligence, and digital health. He has also co-founded seven biotechnology companies and serves as the co-directo

    10/27/25 4:15:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care